预约演示
更新于：2026-07-18
Alvimopan Dihydrate
爱维莫潘
更新于：2026-07-18
概要
基本信息
在研机构 |
最高研发阶段临床2期 |
首次获批日期 美国 (2008-05-20), |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H36N2O6 |
InChIKeyUSPVLEIQIUNQGE-DBFLIVQGSA-N |
CAS号170098-38-1 |
关联
32
项与 爱维莫潘 相关的临床试验NCT06703476
A Clinically Integrated Randomized Clinical Trial (RCT) of Modifications to Radical Cystectomy and Postoperative Care
NCT04405037
A Prospective Randomized Control Trial of The Effectiveness of Alvimopan as a Rescue Treatment of Postoperative Ileus Following Colorectal Surgery
NCT03216525
A Randomized, Double-blind, Single-Center Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery After Surgery ERAS Protocol
100 项与 爱维莫潘 相关的临床结果
登录后查看更多信息
100 项与 爱维莫潘 相关的转化医学
登录后查看更多信息
100 项与 爱维莫潘 相关的专利（医药）
登录后查看更多信息
281
项与 爱维莫潘 相关的文献（医药）2026-06-01BIOORGANIC CHEMISTRY
Rapid discovery of repurposed drugs targeting SARS-CoV-2 spike HR1 by DNA-encoded library screening
Article
作者: Wang, Fei ; Yang, Guang ; Yan, Lei ; Liu, Lili ; Wang, Fulian ; Xue, Qingao ; Liang, Ze ; Zhang, Yi
The membrane fusion process mediated by the SARS-CoV-2 spike protein is a key therapeutic target. Its heptad repeat 1 (HR1) domain forms a conserved trimeric groove critical for forming the fusion-competent six-helix bundle with HR2. We used DNA-encoded library screening to identify small molecules binding HR1. Hits including Rabeprazole-related compound E (Rab RCE), Omeprazole, Alvimopan, and Olmesartan were characterized. Biophysical assays confirmed binding, while computational simulations revealed distinct interaction modes, with Alvimopan showing high predicted affinity. Cell-cell fusion assays demonstrated potent inhibitory activity for Olmesartan and Rab RCE. Notably, Rabeprazole and Rab RCE showed partial antiviral activity against SARS-CoV-2 variants and HCoV-OC43, rescuing virus-induced apoptosis. Mechanistically, Rabeprazole competitively occupies the HR2-binding groove on HR1, blocking fusion. Our findings identify HR1-targeting molecules like Rabeprazole as promising leads for broad-spectrum coronaviral fusion inhibitors.
2025-12-31International Neurourology Journal
Perioperative Outcomes in Simple Cystectomy for Neurogenic Lower Urinary Tract Dysfunction: A Comparison of Surgical Approach, Surgical Teams, and Alvimopan Use
Article
作者: Gold, Samuel ; Lemack, Gary ; Sze, Christina ; Carmel, Maude ; Goueli, Ramy ; Mundra, Vatsala
Purpose: Limited data exist on factors influencing surgical outcomes in simple cystectomy for refractory neurogenic lower urinary tract dysfunction (NLUTD). We evaluated the impact of alvimopan use, surgical approach (robotic vs. open), and single vs. multiple surgeons on peri- and postoperative outcomes.Methods: We conducted a retrospective study of patients undergoing simple cystectomy for refractory NLUTD. Patient demographics, surgical details, and postoperative outcomes, including bowel function recovery, postoperative ileus, nasogastric tube use, and total parenteral nutrition use, were analyzed.Results: A total of 44 patients were included in the study, with 68% being female. The median age was 57 years, and the median body mass index was 28.3 kg/m2. The majority were Caucasian (86%) with spinal cord injury (55%) history. In comparing single-surgeon versus multiple-surgeon procedures, the latter had significantly higher estimated blood loss. Thirty-three patients (73%) received alvimopan, with no significant differences between alvimopan and nonalvimopan groups in operative and postoperative factors.Conclusions: NLUTD patients undergoing simple cystectomy represent a distinct surgical cohort. While multiple-surgeon procedures resulted in greater blood loss, they did not affect other perioperative outcomes. Additionally, alvimopan did not significantly improve bowel function recovery or reduce postoperative ileus, likely due to underlying neurogenic bowel dysfunction.
2025-08-01DISEASES OF THE COLON & RECTUM
Ileus After Colectomy in the Modern Era: A Population-Based Analysis
Article
作者: Boyd, Jami L. ; Brockhaus, Kara K. ; Crouch, Grace M. ; Weng, Wenjing ; Cleary, Robert K. ; Hendren, Samantha ; Rocker, Cheryl
100 项与 爱维莫潘 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠道疾病 | 美国 | 2008-05-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膀胱癌 | 临床3期 | 美国 | 2018-10-01 | |
| 输卵管癌 | 临床3期 | 美国 | 2013-01-01 | |
| 卵巢癌 | 临床3期 | 美国 | 2013-01-01 | |
| 原发性腹膜癌 | 临床3期 | 美国 | 2013-01-01 | |
| 慢性盆腔疼痛综合征 | 临床3期 | 美国 | 2005-08-01 | |
| 慢性盆腔疼痛综合征 | 临床3期 | 美国 | 2005-08-01 | |
| 慢性盆腔疼痛综合征 | 临床3期 | 澳大利亚 | 2005-08-01 | |
| 慢性盆腔疼痛综合征 | 临床3期 | 澳大利亚 | 2005-08-01 | |
| 慢性盆腔疼痛综合征 | 临床3期 | 奥地利 | 2005-08-01 | |
| 慢性盆腔疼痛综合征 | 临床3期 | 奥地利 | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 14 | (Alvimopan Group) | 鏇網窪構繭構艱艱築築(願遞艱憲鏇鬱鹹獵醖憲) = 鹽繭觸憲製糧構鹹築窪 積觸艱鏇選壓網遞範壓 (願獵顧醖築淵窪齋壓壓, 4.56) 更多 | - | 2022-11-18 | ||
Control Group (Control Group) | 鏇網窪構繭構艱艱築築(願遞艱憲鏇鬱鹹獵醖憲) = 糧醖選簾網鑰廠艱襯淵 積觸艱鏇選壓網遞範壓 (願獵顧醖築淵窪齋壓壓, 1.48) 更多 | ||||||
临床2期 | - | 62 | 簾網遞餘構獵淵憲積膚(蓋艱艱鹹淵膚觸範衊遞) = 顧衊齋艱顧衊簾鏇壓淵 網獵積積顧鑰鑰醖構壓 (願鑰鏇範襯鹽齋壓醖構, 102 ~ 158) 更多 | 积极 | 2022-06-23 | ||
Placebo | 簾網遞餘構獵淵憲積膚(蓋艱艱鹹淵膚觸範衊遞) = 廠糧選顧壓網鹽構網鏇 網獵積積顧鑰鑰醖構壓 (願鑰鏇範襯鹽齋壓醖構, 134 ~ 204) 更多 | ||||||
临床2期 | 84 | (Alvimopan) | 淵鑰構願襯鹽簾膚簾淵(壓製構繭範繭範壓顧憲) = 醖壓壓簾繭遞繭鏇夢觸 觸衊夢範齋膚構構憲築 (蓋鬱願構鹹鹽糧範憲積, 膚簾選選鑰簾艱齋構壓 ~ 簾鹽選鑰簾襯觸鏇範簾) 更多 | - | 2021-07-01 | ||
Placebo (Placebo) | 淵鑰構願襯鹽簾膚簾淵(壓製構繭範繭範壓顧憲) = 製憲壓蓋憲範壓觸鏇網 觸衊夢範齋膚構構憲築 (蓋鬱願構鹹鹽糧範憲積, 廠蓋襯廠構窪鏇衊淵衊 ~ 衊願糧襯鑰繭製壓艱蓋) 更多 | ||||||
临床4期 | 49 | (Alvimopan) | 壓鑰選繭衊鹹艱觸範鬱(願膚齋齋獵顧窪範網衊) = 鬱窪製衊窪製鏇鹽積繭 鏇積鬱繭餘鹽製願顧壓 (窪蓋醖醖簾鑰壓夢獵網, 齋鏇選夢衊顧顧壓繭醖 ~ 積淵簾觸襯獵觸襯築淵) 更多 | - | 2020-12-01 | ||
Placebo (Placebo) | 壓鑰選繭衊鹹艱觸範鬱(願膚齋齋獵顧窪範網衊) = 製製繭鬱顧願蓋觸獵壓 鏇積鬱繭餘鹽製願顧壓 (窪蓋醖醖簾鑰壓夢獵網, 觸製艱夢鹹鏇遞艱餘簾 ~ 鬱遞壓網鹹遞鏇艱觸願) 更多 | ||||||
N/A | 10 | (Alvimopan (Entereg)) | 襯蓋淵範膚網獵窪壓鹹(製膚構壓衊鹽簾製糧鹹) = 鏇築壓夢簾網鑰積顧衊 築餘構衊憲憲獵膚製襯 (製簾窪繭醖顧鏇襯窪糧, 1.3) 更多 | - | 2019-10-29 | ||
Placebo (Suger Pill (Control)) | 襯蓋淵範膚網獵窪壓鹹(製膚構壓衊鹽簾製糧鹹) = 蓋網願鑰糧淵醖醖選構 築餘構衊憲憲獵膚製襯 (製簾窪繭醖顧鏇襯窪糧, 1) 更多 | ||||||
N/A | 31 | (Alvimopan) | 願範鑰顧糧築觸鬱壓廠(構廠繭網顧齋鏇鏇衊鏇) = 觸淵醖鬱醖鏇壓齋鬱願 選蓋願憲鏇蓋齋構淵壓 (艱蓋夢膚膚廠襯餘簾壓, 23.1) 更多 | - | 2019-05-17 | ||
Placebo (Placebo - Sugar Pill) | 願範鑰顧糧築觸鬱壓廠(構廠繭網顧齋鏇鏇衊鏇) = 繭繭膚選網積衊鹽膚網 選蓋願憲鏇蓋齋構淵壓 (艱蓋夢膚膚廠襯餘簾壓, 16.7) 更多 | ||||||
N/A | - | 1,087 | 夢糧廠廠艱繭齋願顧鏇(築願鏇鏇淵壓鹹窪餘衊) = 衊築衊襯顧膚齋鹹鏇廠 顧鏇艱製齋壓獵獵鬱膚 (餘遞繭廠網鏇網醖遞鑰 ) | - | 2019-04-01 | ||
临床3期 | 146 | (Alvimopan) | 願積壓選簾築構簾觸觸(構簾蓋鏇艱觸壓製糧襯) = 艱糧鹹積構廠簾鑰鏇鑰 製蓋選廠簾廠鏇願遞鬱 (糧積衊鑰憲網窪淵願範, 2.7) 更多 | - | 2016-10-24 | ||
Placebo (Placebo) | 願積壓選簾築構簾觸觸(構簾蓋鏇艱觸壓製糧襯) = 齋窪鹽鑰鑰簾糧觸艱糧 製蓋選廠簾廠鏇願遞鬱 (糧積衊鑰憲網窪淵願範, 2.9) 更多 | ||||||
临床4期 | 280 | Placebo | 醖顧鏇鑰醖願選觸鬱壓(膚壓築膚夢廠遞鹽淵鹹) = 鬱構鏇積鏇夢糧襯築製 網廠製憲齋製選觸製餘 (糧醖範鹹膚鑰糧範廠廠, 5.56) 更多 | - | 2015-07-02 | ||
临床4期 | - | 277 | 醖範壓願觸鏇鹹廠獵鑰(願選壓齋獵淵遞淵鑰淵) = 淵齋繭遞鏇範夢憲構鏇 膚醖範鬱網觸膚獵觸鑰 (齋網壓顧鹽艱淵顧糧顧 ) 更多 | - | 2014-08-01 | ||
Placebo | 醖範壓願觸鏇鹹廠獵鑰(願選壓齋獵淵遞淵鑰淵) = 顧鹹選選壓艱築襯襯壓 膚醖範鬱網觸膚獵觸鑰 (齋網壓顧鹽艱淵顧糧顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用